• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Expression and role of miRNA in renal cell carcinoma which resists to immunotherapy

Research Project

Project/Area Number 22591773
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeSingle-year Grants
Section一般
Research Field Urology
Research InstitutionFukushima Medical University

Principal Investigator

ISHIBASHI Kei  福島県立医科大学, 医学部, 講師 (90347211)

Co-Investigator(Kenkyū-buntansha) SHISHIDO Keiichi  福島県立医科大学, 医学部, 博士研究員 (30285035)
Project Period (FY) 2010 – 2012
Project Status Completed (Fiscal Year 2012)
Budget Amount *help
¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
Fiscal Year 2012: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2011: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2010: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Keywords腫瘍学 / 腎癌 / インターフェロン / IL-6 / SOCS3 / miRNA
Research Abstract

Interferon (IFN)-α is one of the most commonly used agents in immunotherapy for patients with advanced -stage renal cell carcinoma. However, because of the drug resistance to IFN-α, its benefits are limited. In this study, we evaluated theexpression of hsa-miR-93 or SOCS3-mRNA in renal cell carcinoma cells which resists to IFN treatment. Among the renal cell carcinoma cell lines which we used in this study, 786-O cells showed resistance to IFN treatment. The expression of both hsa-miR-93 and SOCS3-mRNA was significantly higher compared with other cell lines. Suppression of hsa-miR-93 or SOCS3-mRNA induced sensitivity to IFN in 786-O cells. Especially, down regulation of SOCS3-mRNA enhanced STAT1 activation and anti-tumor activity of IFN, both in vitro and in vivo, in a human IFN- resistant RCC cell line 786-O. Because IL-6 receptor antibody blocked SOCS3 efficiently, combination therapy using an antihuman IL-6R antibody with IFN-α may represent a novel therapeutic approach for the treatment of renal cell carcinoma.

Report

(4 results)
  • 2012 Annual Research Report   Final Research Report ( PDF )
  • 2011 Annual Research Report
  • 2010 Annual Research Report
  • Research Products

    (10 results)

All 2013 2012 2011

All Journal Article (4 results) (of which Peer Reviewed: 2 results) Presentation (6 results)

  • [Journal Article] Humanised antihuman IL-6R antibody with interferon inhibits renal cell carcinoma cell growth in vitro and in vivo through suppressed SOCS3 expression.2013

    • Author(s)
      Oguro T
    • Journal Title

      Eur J Cancer

      Volume: May;49(7) Issue: 7 Pages: 1715-24

    • DOI

      10.1016/j.ejca.2012.11.038

    • Related Report
      2012 Annual Research Report
    • Peer Reviewed
  • [Journal Article] Equally contributed Humanised antihuman IL-6R antibody with interferon inhibits renal cell carcinoma cell growth in vitro and in vivo through suppressed SOCS3 expression2012

    • Author(s)
      Oguro T, Ishibashi K, Sugino T, Hashimoto K, Tomita S, Takahashi N, Yanagida T, Haga N, Aikawa K, Suzutani T, Yamaguchi O, Kojima Y
    • Journal Title

      European J Cancer

      Volume: 26

    • Related Report
      2012 Final Research Report
  • [Journal Article] Equally contributed Suppression of SOCS3 increases susceptibility of renal cell carcinoma to INF-α2011

    • Author(s)
      Tomita S, Ishibashi K , Hashimoto K, Sugino T, Yanagida T, Kushida N, Shishido K, Aikawa K, Sato Y, Suzutani T, Yamaguchi O
    • Journal Title

      Cancer Sci

      Volume: 102(1) Pages: 57-63

    • Related Report
      2012 Final Research Report
  • [Journal Article] Suppression of SOCS3 increases susceptibility of renal cell carcinoma to INF-α2011

    • Author(s)
      S.Tomita, K.Ishibashi, et. al.
    • Journal Title

      Cancer Science

      Volume: Jan;102(1) Pages: 57-63

    • Related Report
      2010 Annual Research Report
    • Peer Reviewed
  • [Presentation] IL-6 and SOCS3 regulates cell proliferation in renal cell carcinoma cells AUA2013

    • Author(s)
      Kei Ishibashi, Toshiki Oguro; Shin Kumagai; Masao Kataoka; Hidenori Akaihata; Ken Aikawa; Yoshiyuki Kojima
    • Place of Presentation
      SanDiego USA.
    • Year and Date
      2013-04-08
    • Related Report
      2012 Final Research Report
  • [Presentation] Combination therapy with humanized antihuman IL-6R antibody and interferon-α successfully prevents the growth of 786-O renal cell carcinoma cells2013

    • Author(s)
      Kei Ishibashi, Toshiki Oguro; Shin Kumagai; Norio Takahashi; Nobuhiro Haga; Masanori Nomiya; Tomohiko Yanagida; Ken Aikawa Yoshiyuki Kojima
    • Place of Presentation
      SanDiego USA
    • Related Report
      2012 Final Research Report
  • [Presentation] Combination therapy with humanized antihuman IL-6R antibody and interferon-a successfully prevents the growth of 786-O renal cell carcinoma cells.2013

    • Author(s)
      Ishinashi K
    • Organizer
      AUA
    • Place of Presentation
      SanDIego, USA
    • Related Report
      2012 Annual Research Report
  • [Presentation] IL-6 and SOCS3 regulates cell proliferation in renal cell carcinoma cells2013

    • Author(s)
      Ishibashi K
    • Organizer
      AUA
    • Place of Presentation
      SanDIego, USA
    • Related Report
      2012 Annual Research Report
  • [Presentation] Kojima TOCILIZUMAB CAN ENHANCE THE ANTI-TUMOR EFFECT OF IFN-a IN RENAL CELL CARCINOMA2012

    • Author(s)
      T. Oguro, K. Ishibashi, T. Sugino, S. Kumagai, N. Takahashi, N. Haga, T. Yanagida, K. Aikawa, O. Yamaguchi, Y.
    • Organizer
      37th ESMO Congress
    • Place of Presentation
      Vienna
    • Related Report
      2012 Final Research Report
  • [Presentation] Tocilizumab can enhance the anti-tumor effect of IFN-? in renal cell carcinoma2012

    • Author(s)
      Oguro T
    • Organizer
      ESMO
    • Place of Presentation
      Viena
    • Related Report
      2012 Annual Research Report

URL: 

Published: 2010-08-23   Modified: 2019-07-29  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi